MX2012013075A - Metodos novedosos para preparacion de antagonistas p2x7r. - Google Patents

Metodos novedosos para preparacion de antagonistas p2x7r.

Info

Publication number
MX2012013075A
MX2012013075A MX2012013075A MX2012013075A MX2012013075A MX 2012013075 A MX2012013075 A MX 2012013075A MX 2012013075 A MX2012013075 A MX 2012013075A MX 2012013075 A MX2012013075 A MX 2012013075A MX 2012013075 A MX2012013075 A MX 2012013075A
Authority
MX
Mexico
Prior art keywords
preparation
novel methods
p2x7r antagonists
p2x7r
antagonists
Prior art date
Application number
MX2012013075A
Other languages
English (en)
Inventor
Michael Boes
Original Assignee
Affectis Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affectis Pharmaceuticals Ag filed Critical Affectis Pharmaceuticals Ag
Publication of MX2012013075A publication Critical patent/MX2012013075A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención describe métodos novedosos para la síntesis de compuestos de N-indol-3-il-alquilamida sustituido los cuales actúan como antagonistas P2X7R, estos métodos involucran la transposición de un intermediario de oxima.
MX2012013075A 2010-05-14 2011-03-04 Metodos novedosos para preparacion de antagonistas p2x7r. MX2012013075A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10162812 2010-05-14
PCT/EP2011/053283 WO2011141194A1 (en) 2010-05-14 2011-03-04 Novel methods for the preparation of p2x7r antagonists

Publications (1)

Publication Number Publication Date
MX2012013075A true MX2012013075A (es) 2012-12-17

Family

ID=43924014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013075A MX2012013075A (es) 2010-05-14 2011-03-04 Metodos novedosos para preparacion de antagonistas p2x7r.

Country Status (13)

Country Link
US (1) US20130060047A1 (es)
EP (2) EP2569281A1 (es)
JP (1) JP2013526496A (es)
CN (1) CN102858741A (es)
AU (1) AU2011252351A1 (es)
BR (1) BR112012028850A2 (es)
CA (1) CA2799115A1 (es)
EA (1) EA201201548A1 (es)
IL (1) IL222948A0 (es)
MX (1) MX2012013075A (es)
SG (1) SG185400A1 (es)
WO (1) WO2011141194A1 (es)
ZA (1) ZA201209495B (es)

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2930798A (en) * 1956-08-03 1960-03-29 Clin Byla Ets 3-alkanoyl 1-tertiary-amino-alkyl indol oximes and production thereof
GB832568A (en) * 1956-08-03 1960-04-13 Clin Byla Ets Heterocyclic compounds and production thereof
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SK13422001A3 (sk) 1999-04-09 2002-05-09 Astrazeneca Ab Adamantánové deriváty
SE9901875D0 (sv) 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
WO2003047515A2 (en) 2001-11-30 2003-06-12 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services P2x7 receptor antagonists
JP2005517684A (ja) 2001-12-21 2005-06-16 キング ファーマシューティカルズ リサーチ アンド ディベロップメント インコーポレイテッド チロシル誘導体及びｐ２ｘ７受容体モジュレーターとしてのそれらの使用
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
JP2006508145A (ja) * 2002-11-15 2006-03-09 テイボテク・フアーマシユーチカルズ・リミテツド 抗感染化合物としての置換インドールピリジニウム
MXPA05007130A (es) 2002-12-31 2005-08-26 Pfizer Prod Inc Inhibidores benzamida del receptor p2x7.
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
ATE355273T1 (de) 2003-05-12 2006-03-15 Pfizer Prod Inc Benzamidinhibitoren des p2x7-rezeptors
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
SE0302139D0 (sv) 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
WO2005019182A1 (en) 2003-08-20 2005-03-03 Bayer Healthcare Ag Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists
GB2422782A (en) 2003-10-21 2006-08-09 Inspire Pharmaceuticals Inc Non-nucleotide compositions and method for treating pain
EP1747206A1 (en) 2004-04-29 2007-01-31 Abbott Laboratories Amino-tetrazoles analogues and methods of use
KR20070011588A (ko) * 2004-05-17 2007-01-24 티보텍 파마슈티칼즈 리미티드 치환된 1-페닐-1,5-디히드로-피리도-[3,2-ｂ]인돌-2-온 및다른 ｈｉｖ 억제제의 배합물
AR049340A1 (es) * 2004-05-17 2006-07-19 Tibotec Pharm Ltd 1- heterociclil - l, 5- dihidro- pirido (3,2-b) indol - 2- onas
CN1976930B (zh) * 2004-05-17 2011-01-19 泰博特克药品有限公司 用作抗感染药物的6,7,8,9-取代的1-苯基-1,5-二氢吡啶并(3,2-b)吲哚-2-酮
EP1776352A1 (en) 2004-06-29 2007-04-25 Pfizer Products Inc. Method for preparing 5-[4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h[1,2,4]triazin-2-yl]-benzamide derivatives by deprotecting the hydroxyl-protected precursers
AU2005258924A1 (en) 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-`1,2,4!-triazin-2-YK!benzamide derivatives with P2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid
US7241776B2 (en) 2004-08-02 2007-07-10 Abbott Laboratories Cyanoamidine P2X7 antagonists for the treatment of pain
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
BRPI0519287A2 (pt) 2004-12-24 2009-01-06 Astrazeneca Ab derivados de amida
US20080146612A1 (en) 2005-01-27 2008-06-19 Astrazeneca Ab Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor
US20060211739A1 (en) 2005-02-08 2006-09-21 Arturo Perez-Medrano Use of selective P2X7 receptor antagonists
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
EP1885376A1 (en) 2005-05-05 2008-02-13 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US20090124555A1 (en) 2005-08-29 2009-05-14 Irma Bernatchez-Lemaire Use of histogranin and histogranin-like compounds as inhibitors of p2x7 receptor function and as anti-arthritic agents
US20100022531A1 (en) 2005-09-01 2010-01-28 Renovis, Inc. Novel compounds as p2x7 modulators and uses thereof
EP1951689A1 (en) 2005-11-07 2008-08-06 Abbott Laboratories P2x7 receptor antagonists and methods of use
JP2009514952A (ja) 2005-11-09 2009-04-09 アボット・ラボラトリーズ Ｐ２ｘ７受容体拮抗薬としての２−フェニル−２ｈ−ピラゾール誘導体およびそれの使用
US20100184802A1 (en) 2006-03-16 2010-07-22 Kelly Michael G Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof
WO2007109154A2 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
MX2008011919A (es) 2006-03-16 2008-11-28 Renovis Inc Compuestos de bicicloheteroarilo como moduladores de p2x7 y usos de los mismos.
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
JP5306987B2 (ja) 2006-03-16 2013-10-02 エボテック （ユーエス） インコーポレイテッド Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用
WO2007109182A2 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007141267A1 (en) 2006-06-06 2007-12-13 Glaxo Group Limited N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration
GB0611154D0 (en) 2006-06-06 2006-07-19 Glaxo Group Ltd Novel receptor antagonists and their methods of use
WO2008005368A2 (en) 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
SI2049478T1 (sl) 2006-07-06 2012-08-31 Glaxo Group Ltd Substituirani N-fenilmetil-5-okso-prolin-2-amidi kot antagonisti receptorja P2X7 in postopki za njihovo uporabo
AU2010237302A1 (en) * 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use

Also Published As

Publication number Publication date
ZA201209495B (en) 2013-08-28
IL222948A0 (en) 2012-12-31
CN102858741A (zh) 2013-01-02
JP2013526496A (ja) 2013-06-24
EP2569281A1 (en) 2013-03-20
EA201201548A1 (ru) 2013-05-30
WO2011141194A1 (en) 2011-11-17
BR112012028850A2 (pt) 2015-09-15
AU2011252351A1 (en) 2012-10-11
CA2799115A1 (en) 2011-11-17
EP2386541A1 (en) 2011-11-16
US20130060047A1 (en) 2013-03-07
SG185400A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
PH12015500263A1 (en) New bicyclic derivatives
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MD20150091A2 (ro) Compuşi antivirali
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MX2012007507A (es) Compuestos de heteroarilo y usos de los mismos.
MY181898A (en) Heterocyclic compounds and uses thereof
IN2014CN04160A (es)
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
UA111186C2 (uk) Способи та композиції для одержання норибогаїну з воакангіну
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
EA201490756A1 (ru) Разагилина цитрамид
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
MX360872B (es) Nuevas composiciones para la produccion de poliamidas coladas.
WO2012063115A3 (en) Process for the preparation of rosuvastatin calcium via novel amine intermediate
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
IN2014DN09451A (es)
IN2014DN10209A (es)
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
WO2014008204A3 (en) Structures of proteasome inhibitors and methods for synthesizing and use thereof
IL226132A0 (en) A process for the preparation of n-(benzyl)cyclopropaneamines converted by imine hydrogenation
WO2012139074A3 (en) Migrastatins and uses thereof
MX346980B (es) Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona.
MX2012013075A (es) Metodos novedosos para preparacion de antagonistas p2x7r.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal